Compare Johnson & Johnson (JNJ) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Johnson & Johnson trades at $261.41 (market cap $618.09B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: Johnson & Johnson is far larger — about 35.3× iShares Broad USD Investment Grade Corporate Bond's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| JNJ | USIG | |
|---|---|---|
Market Cap | $618.09B | $17.53B |
Volume | 6,050,983 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $278.43 | $52.69 |
52-Week Low | $186.00 | $48.54 |
Typical Hold Time | 129 Days | 44 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
USIG trades at $48.77 with minimal daily movement (+0.18%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators remain neutral. The ETF maintains regular dividend distributions with recent payouts of $0.20-$0.21 per share. Institutional activity includes Blue Edge Capital establishing a new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in long-term credit quality. Key risks include credit spread volatility and macroeconomic sensitivity, while the steady dividend stream provides income stability for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
